PT - JOURNAL ARTICLE AU - KOH, HYEON KANG AU - CHIE, EUI KYU AU - KIM, KYUBO AU - JANG, JIN-YOUNG AU - KIM, SUN WHE AU - OH, DO-YOUN AU - IM, SEOCK-AH AU - BANG, YUNG-JUE AU - HA, SUNG W. TI - Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy DP - 2016 Oct 01 TA - Anticancer Research PG - 5455--5461 VI - 36 IP - 10 4099 - http://ar.iiarjournals.org/content/36/10/5455.short 4100 - http://ar.iiarjournals.org/content/36/10/5455.full SO - Anticancer Res2016 Oct 01; 36 AB - Aim: To analyze the outcomes of patients with unresectable pancreatic cancer after chemoradiotherapy (CCRT), focusing on sequencing strategy. Patients and Methods: Data of 144 patients treated from January 1989 to December 2013 were retrospectively analyzed. Patients were divided into the scheduled group (N=27), salvage group (N=37) and upfront group (N=80) per CCRT and chemotherapy sequence. Results: With a median follow-up of 10.4 months (range=1.4-164.2), median overall survival (OS) was 13.5 months. Patients in the upfront group had inferior performance status and received a lower radiation dose (p=0.007 and p<0.001, respectively). Higher radiation dose (≥45 Gy) was the sole prognosticator related with improved survival in multivariate (p=0.001) analysis, whereas treatment sequence was not a significant prognostic factor (p=0.409). Conclusion: No difference was found among tested sequencing strategies that were all well-tolerated, despite skewed distribution for performance and radiation dose. An upfront approach may be a viable option for patients with limited performance to undergo more active systemic chemotherapy.